Roche Diagnostics India Introduces NT-proBNP Test for Diabetic Patients at Risk of Cardiovascular Disease (CVD) on ET HealthWorld

Roche Diagnostics India has introduced a new point-of-care (PoC) NT-proBNP test aimed at screening diabetes patients at risk of cardiovascular diseases (CVD), such as heart failure (HF). The test, available exclusively on the cobas h 232 system, is designed to provide faster and more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D).

Patients with diabetes face a higher risk of developing CVD, with statistics showing that up to 46% of diabetic patients will develop CVD in their lifetime. CVD is responsible for about 50% of mortality in T2D patients, with approximately 30% of diabetic patients developing HF during their lifetime. Early detection of HF is crucial, as individuals with T2D and HF face up to an 8x increased risk of death compared to those without HF.

The NT-proBNP test on the cobas h 232 system facilitates early detection and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions. According to Dr. Sanjay Kalra, Chief Endocrinologist at Bharti Hospital in Karnal, India, the incorporation of the NT-proBNP test extension onto convenient point-of-care platforms is a significant advancement in diabetes care, allowing for proactive assessment of heart failure risks in T2D patients.

Dr. Rishubh Gupta, Managing Director of Roche Diagnostics India & Neighbouring Markets, emphasized that the extended claim on the NT-proBNP test on their point-of-care system reflects their commitment to empowering clinicians with cutting-edge tools for early diagnosis and personalized patient care. The NT-proBNP test for diabetes at point-of-care signifies a milestone in the journey towards proactive and personalized healthcare for T2D patients.